ORLANDO — Irritable bowel syndrome with diarrhea found further definition this year with pinpointing causes and improved treatments, according to one expert at the World Congress of Gastroenterology at ACG 2017.
“We continue to see advances in the diagnosis and the treatment of irritable bowel syndrome,” Mark Pimentel, MD, executive director of the Medically Associated Science and Technology program at Cedars Sinai, said in this exclusive video perspective. “This is really a remarkable year because for the first time, we can say for sure that a good component of IBS with diarrhea starts with acute gastroenteritis.”
Pimentel said a Mayo Clinic study showing this connection further points to the role of the microbiome in IBS.
Additionally, posters presented at this meeting by Pimentel and colleagues showed that Xifaxan (rifaximin, Salix Pharmaceuticals) produced a response in 36% of patients without relapse for up to 6 months.
“This is a really exciting time for this disease state. More importantly, this is a really exciting time for patients because we’re starting to get to the meat of the issue,” he said.
Klem F, et al. Gastroenterology. 2017 Apr;152(5):1042-1054.e1. doi:10.1053/j.gastro.2016.12.039.
Lembo AJ. Poster 1148. Presented at: World Congress of Gastroenterology at American College of Gastroenterology Annual Scientific Meeting; Oct. 13-18, 2017; Orlando, FL.
Pimentel M. Poster 2025. Presented at: World Congress of Gastroenterology at American College of Gastroenterology Annual Scientific Meeting; Oct. 13-18, 2017; Orlando, FL.
: Pimentel reports he is a consultant and has received grant/research support from Salix Pharmaceuticals. Cedars-Sinai Medical Center has a licensing agreement with Salix Pharmaceuticals.